Biological Products, Stocks
103 biological products, stocks with fundamental analysis, valuation charts, and SEC filing data. Industry median P/E is 22.7, median ROIC -42.1%, and combined market cap of $662.9B.
Amgen discovers, develops, manufactures, and delivers innovative medicines to treat serious diseases, operating as a single human therapeutics segment with a presence in approximately 100 countries.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers innovative medicines to address unmet medical needs in virology, oncology, and other therapeutic areas across more.
Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering innovative therapies for serious and complex diseases, with a concentrated portfolio in neurology, speci.
Moderna is a pioneer in mRNA medicine with a platform technology that enables the development of vaccines and therapeutics across infectious disease, oncology, and rare disease.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunologi.
Exelixis is an oncology company developing small-molecule and biotherapeutic medicines for cancer treatment, with cabozantinib as its flagship product generating the majority of revenues.
Bio-Techne develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally.
Halozyme Therapeutics is a biopharmaceutical company that develops and licenses proprietary drug delivery technologies to enable subcutaneous administration of injectable biologics and small molecules.
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems enabling more efficient manufacturing of biological drugs, including mono.